DMD and proximal spinal muscular atrophy: We were able to access this information in the company submissions for two NICE Highly Specialised Technology appraisals: ataluren for treating Duchenne muscular dystrophy (DMD) with a nonsense mutation in the dystrophin gene [29] and onasemnogene abeparvovec for treating spinal muscular atrophy (SMA) [30].